Top Ten most popular articles on Pharmafile.com this week
pharmafile | May 24, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top tenÂ
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories in the pharmaceutical industry. From new positive data for Janssen’s esketamine depression treatment and the news that MSD has agreed to buy Peloton Therapeutics for $2.1 billion, to pushes from Alexandria Ocasio-Cortez to grill Gilead’s CEO on why its HIV prevention drug is more than 200 times more expensive in US than elsewhere, check out the 10 most popular stories on the website this week.
10. New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression
New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the FDA in the US in combination with oral antidepressants earlier this year.
9. The global rise in antibiotic resistance threatens infection prevention and cure
Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional incentivisation initiatives needed to promote innovation, as well as the role of preventative antimicrobial treatments as an important element of this global fight against AMR.
8. Takeda’s Entyvio beats Humira for remission in ulcerative colitis, exploratory data show
Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its superiority over AbbVie’s best-selling anti-tumour necrosis factor-alpha (anti-TNFα) therapy Humira (adalimumab) in achieving remission in moderately to severely active ulcerative colitis (UC).
7. Amgen agrees to buy Nuevolution for $167 million
California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).
6. MSD buys Peloton Therapeutics in deal worth $2.1 billion
US firm MSD will pay Texas-based biotech Peloton Therapeutics $1 billion upfront and a further $1.15 billion based on the achievement of regulatory and sales milestones.
5. Gilead CEO Daniel O’Day challenged over patents on PrEP drug Truvada
US Representative Alexandria Ocasio-Cortez tore into Gilead CEO Daniel O’Day on Thursday, over the firm’s nearly $2,000 price tag on PrEP drug, Truvada, in the United States. Sold at a list price of $1,780 in the US, the drug costs just $8 in Australia.
4. Drugmakers colluded to drive up price of anti-nausea drug by 700%
Four pharmaceutical firms have been accused of illegally colluding to restrict the supply of anti-nausea medication Prochlorperazine after the price of the drug increased by 700%.
3. Insider Interview: Paving paths in prostate cancer
Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses Janssen’s vision in Oncology and how the company is building on its heritage in prostate cancer to deliver transformational outcomes for patient.
2. Sandoz is first multinational to secure generic approval under new Chinese guidelines
Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in China from the country’s National Medical Products Administration (NMPA). The therapy was indicated for the reduction of heart disease risk and prevention of stroke and heart attack.
1. J&J to invest €100 million into Limerick manufacturing facilities creating 100 new jobs
Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care manufacturing facilities in Limerick. The expansion is expected to see the creation of 100 new jobs.
Related Content
Gilead’s HIV treatment meets primary trial endpoint
Gilead has announced positive topline results from its phase 3 ARTISTRY-2 trial, which evaluated a …
Sandoz launches two new bone disease biosimilars in Europe
Sandoz has announced the European launch of two new bone disease biosimilars. Wyost (denosumab 120 …
Gilead announces first shipments of HIV prevention drug to Eswatini and Zambia
Gilead has announced the first shipments of its HIV prevention drug lenacapavir to Eswatini and …
